Nuformix Share News (NFX)
NFX Share
NFX Share
NFX Share
NFX Share
NFX
NFX Share
NFX Level 2
NFX Live
NFX Broker
NFX Directors
NFX Financial
NFX
NFX Short
NFX
Last checked at -
(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreNuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.
Read moreNuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.
Read more(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.
Read moreNuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.
Read moreTRADING UPDATES: Round Hill Music buys Alice In Chains catalogue
Read moreSMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract
Read moreTRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows
Read moreIN BRIEF: Nuformix notes positive results for inhaled NXP002 dose
Read moreTRADING UPDATES: Princess exits Taco Bell; Nuformix files patent
Read moreSMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay
Read moreCORRECT: Nuformix Chair Alastair Riddell to move to executive chair
Read more
Last checked at